|
Market Closed -
Nasdaq
21:00:00 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 115.71 USD | -1.04% |
|
+2.15% | +17.15% |
| 10-22 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 10-22 | Leerink Partners Adjusts Price Target on Incyte to $154 From $155 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INCYTE CORPORATION | Biopharmaceuticals | -1.04% | +2.15% | +17.15% | +31.40% | +75.88% | 22.99B |  |  | |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
